Aspirin resistance: Prevalence and clinical outcome in Egypt
Introduction: The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response t...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2015-04-01
|
Series: | Egyptian Journal of Critical Care Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2090730314000309 |
id |
doaj-01bc188467634762985d918867aa3c3d |
---|---|
record_format |
Article |
spelling |
doaj-01bc188467634762985d918867aa3c3d2020-11-25T02:16:08ZengWolters KluwerEgyptian Journal of Critical Care Medicine2090-73032015-04-0131232710.1016/j.ejccm.2014.12.001Aspirin resistance: Prevalence and clinical outcome in EgyptAhmed SalahMohammed El-DesukyAmal RizkAmr El-HadidyIntroduction: The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to aspirin may be an explanation for some of these events. Multiple trials have linked aspirin resistance to these adverse events. Objectives: The aim of this study was to estimate the prevalence of aspirin resistance among patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome. Methods: A total of 50 patients with documented history of CAD were included; they were on aspirin 150 mg/day for more than seven days and no other antiplatelet drugs. They were evaluated for aspirin resistance using light transmission aggregometry. Aspirin resistance was defined as a mean aggregation of >20% with 0.5 mg/ml arachidonic acid. They were followed up after six months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke. Results: Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was significantly higher in patients with family history of CAD (p = 0.044), smoking (p = 0.011), history of MI (p = 0.024), history of percutaneous coronary intervention (PCI) (p = 0.001), and concomitant NSAIDs intake (p = 0.047). Moreover, aspirin resistance was more common among patients with multi-vessel CAD (p = 0.024). Aspirin-resistant patients had a significantly higher rate of UA (p = 0.001) and all major adverse cardiac events (MACE) (p < 0.001).http://www.sciencedirect.com/science/article/pii/S2090730314000309Aspirin resistanceCoronary artery diseaseClinical outcome |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ahmed Salah Mohammed El-Desuky Amal Rizk Amr El-Hadidy |
spellingShingle |
Ahmed Salah Mohammed El-Desuky Amal Rizk Amr El-Hadidy Aspirin resistance: Prevalence and clinical outcome in Egypt Egyptian Journal of Critical Care Medicine Aspirin resistance Coronary artery disease Clinical outcome |
author_facet |
Ahmed Salah Mohammed El-Desuky Amal Rizk Amr El-Hadidy |
author_sort |
Ahmed Salah |
title |
Aspirin resistance: Prevalence and clinical outcome in Egypt |
title_short |
Aspirin resistance: Prevalence and clinical outcome in Egypt |
title_full |
Aspirin resistance: Prevalence and clinical outcome in Egypt |
title_fullStr |
Aspirin resistance: Prevalence and clinical outcome in Egypt |
title_full_unstemmed |
Aspirin resistance: Prevalence and clinical outcome in Egypt |
title_sort |
aspirin resistance: prevalence and clinical outcome in egypt |
publisher |
Wolters Kluwer |
series |
Egyptian Journal of Critical Care Medicine |
issn |
2090-7303 |
publishDate |
2015-04-01 |
description |
Introduction: The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to aspirin may be an explanation for some of these events. Multiple trials have linked aspirin resistance to these adverse events.
Objectives: The aim of this study was to estimate the prevalence of aspirin resistance among patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome.
Methods: A total of 50 patients with documented history of CAD were included; they were on aspirin 150 mg/day for more than seven days and no other antiplatelet drugs. They were evaluated for aspirin resistance using light transmission aggregometry. Aspirin resistance was defined as a mean aggregation of >20% with 0.5 mg/ml arachidonic acid. They were followed up after six months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke.
Results: Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was significantly higher in patients with family history of CAD (p = 0.044), smoking (p = 0.011), history of MI (p = 0.024), history of percutaneous coronary intervention (PCI) (p = 0.001), and concomitant NSAIDs intake (p = 0.047). Moreover, aspirin resistance was more common among patients with multi-vessel CAD (p = 0.024). Aspirin-resistant patients had a significantly higher rate of UA (p = 0.001) and all major adverse cardiac events (MACE) (p < 0.001). |
topic |
Aspirin resistance Coronary artery disease Clinical outcome |
url |
http://www.sciencedirect.com/science/article/pii/S2090730314000309 |
work_keys_str_mv |
AT ahmedsalah aspirinresistanceprevalenceandclinicaloutcomeinegypt AT mohammedeldesuky aspirinresistanceprevalenceandclinicaloutcomeinegypt AT amalrizk aspirinresistanceprevalenceandclinicaloutcomeinegypt AT amrelhadidy aspirinresistanceprevalenceandclinicaloutcomeinegypt |
_version_ |
1724892624129622016 |